The mechanism of action of these drugs is unique. Both taxanes bind preferentially and reversibly to the a-subunit of tubulin in microtubules (Pazdur et al., 1993 (Pazdur et al., 1993) . This seems even better than the results of recent studies with frequently used combinations of drugs. Remarkably, the response rate in second-line chemotherapy (62%) is only slightly lower than in first-line chemotherapy, which again is an uncommon observation. Such data have been unprecedented in this disease and do justify a degree of enthusiasm. Very good response rates have also been reported in ovarian cancer, head and neck cancer, small-cell lung cancer, malignant Br. J. Cancer (1994), 70, 183-184 melanoma. pancreatic cancer and soft-tissue sarcomas.
Beside the positive messaze of activity. the development of docetaxel also has led to specific problems. particularly the recoznition of some burdensome side-effects. In contrast to paclitaxel. hypersensitivity reactions are less frequent and can easilY be prevented by proper premedication. Some of the side-effects of docetaxel. such as alopecia. frequent but most often uncomplicated short-lasting neutropenia and less frequent and usually mild nausea and or voomiting. diarrhoea and mucositis. are not uncommon with other cytotoxic drugs. Unusual side-effects include mild and easily treatable arthralgia mval ia and skin toxicity and fluid retention (the latter beinz related to the cumulative dose) which are much more problematic. Most experience to date has been obtained in patients who have not received routine premedication treatment. as is usual with paclitaxel. Skin toxicity consists of er-thema. desquamation and infrequent exfoliation and or nail toxicity-consisting of discoloration and sometimes painful onvcholysis. Most frequently fluid retention consists of peripheral edema. but pleural effusions and ascites have also been reported. Data on how to manage or prevent these side-effects are certainlv not conclusive. and studies on various premedication regimens are ongoing. Of course. paclitaxel also has some side-effects. such as cardiotoxicitv and neurotoxicity. which do not. however. appear to be a problem with docetaxel. However. it should not be forgotten that the most active and frequently used drug in the treatment of solid tumors. cisplatin. has major side-effects that incapacitated the first patients treated with this drug. Over the y-ears we have learned how to deal with these side-effects. and presently cisplatin is used in many non-specialised hospitals. As lonz as studies on the pathogenesis of the side-effects continue to be performed and the majority of patients treated with docetaxel are treated in specialist centres and properly monitored. there is a good chance that specific measures to prevent nail toxicitx and fluid retention will be found. This will enable prolonged treatment. which may be of relevance for patients with metastatic disease. Short-lasting treatment for 5-6 cycles already seems quite feAsible. Therefore. combination chemotherapy regimens including docetaxel should further be studied. In addition. docetaxel could become an attractive option for studies on adjuvant chemotherapy in breast cancer.
